Cargando…
Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials
BACKGROUND: Few validated instruments exist for use in hidradenitis suppurativa (HS) trials. OBJECTIVES: To develop a novel HS Investigator Global Assessment (HS‐IGA) and to validate its psychometric properties. METHODS: Development of HS‐IGA involved discussion among stakeholders, including patient...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542331/ https://www.ncbi.nlm.nih.gov/pubmed/35599448 http://dx.doi.org/10.1111/bjd.21236 |
_version_ | 1784804126900617216 |
---|---|
author | Garg, Amit Zema, Carla Kim, Katherine Gao, Weihua Chen, Naijun Jemec, Gregor B.E. Kirby, Joslyn Thorlacius, Linnea Villumsen, Bente Ingram, John R. |
author_facet | Garg, Amit Zema, Carla Kim, Katherine Gao, Weihua Chen, Naijun Jemec, Gregor B.E. Kirby, Joslyn Thorlacius, Linnea Villumsen, Bente Ingram, John R. |
author_sort | Garg, Amit |
collection | PubMed |
description | BACKGROUND: Few validated instruments exist for use in hidradenitis suppurativa (HS) trials. OBJECTIVES: To develop a novel HS Investigator Global Assessment (HS‐IGA) and to validate its psychometric properties. METHODS: Development of HS‐IGA involved discussion among stakeholders, including patients, within HISTORIC. Data from replicate phase III randomized controlled trials evaluating HS treatment were utilized. Multivariate models identified lesion type and body region as variables of importance. Classification and regression trees for ordinal responses were built. Validation included assessment of test–retest reliability, predictive validity, responsiveness and clinical meaningfulness. RESULTS: There were 3024 unique measurements available in PIONEER I. Mean and median lesion counts by region were largely <10 and were highest in axillary and inguinal regions. The mean and median number of regions involved were ≤ 3 for individual lesions and combinations. Regardless of lesion type, axillary and inguinal regions most influenced the HS‐IGA score. Accordingly, regions were combined into a six‐point IGA based on the maximum lesion number in either upper or lower body regions with a score of 0 (0–1 lesions), 1 (2–5), 2 (6–10), 3 (11–15), 4 (16–20) and 5 (≥ 20 lesions). The intraclass correlation coefficient for test–retest reliability was 0·91 (95% confidence interval 0·87–0·94). Spearman’s rank order correlations (SROCs) with HS‐PGA and Hidradenitis Suppurativa Clinical Response (HiSCR) were 0·73 and 0·51, respectively (P < 0·001 for both comparisons). SROCs with Dermatology Life Quality Index (DLQI), pain numerical rating scale and HS‐QoL were 0·42, 0·34 and –0·25, respectively (P < 0·001 for all comparisons). HS‐IGA was responsive at weeks 12 and 36. Predictive convergent validity was very good with HS‐PGA (area under the curve = 0·89) and with HiSCR (area under the curve = 0·82). Predictive divergent validity was low with DLQI and HS‐QoL. CONCLUSIONS: HS‐IGA has moderate‐to‐strong psychometric properties and is simple to calculate. |
format | Online Article Text |
id | pubmed-9542331 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95423312022-10-14 Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials Garg, Amit Zema, Carla Kim, Katherine Gao, Weihua Chen, Naijun Jemec, Gregor B.E. Kirby, Joslyn Thorlacius, Linnea Villumsen, Bente Ingram, John R. Br J Dermatol Original Articles BACKGROUND: Few validated instruments exist for use in hidradenitis suppurativa (HS) trials. OBJECTIVES: To develop a novel HS Investigator Global Assessment (HS‐IGA) and to validate its psychometric properties. METHODS: Development of HS‐IGA involved discussion among stakeholders, including patients, within HISTORIC. Data from replicate phase III randomized controlled trials evaluating HS treatment were utilized. Multivariate models identified lesion type and body region as variables of importance. Classification and regression trees for ordinal responses were built. Validation included assessment of test–retest reliability, predictive validity, responsiveness and clinical meaningfulness. RESULTS: There were 3024 unique measurements available in PIONEER I. Mean and median lesion counts by region were largely <10 and were highest in axillary and inguinal regions. The mean and median number of regions involved were ≤ 3 for individual lesions and combinations. Regardless of lesion type, axillary and inguinal regions most influenced the HS‐IGA score. Accordingly, regions were combined into a six‐point IGA based on the maximum lesion number in either upper or lower body regions with a score of 0 (0–1 lesions), 1 (2–5), 2 (6–10), 3 (11–15), 4 (16–20) and 5 (≥ 20 lesions). The intraclass correlation coefficient for test–retest reliability was 0·91 (95% confidence interval 0·87–0·94). Spearman’s rank order correlations (SROCs) with HS‐PGA and Hidradenitis Suppurativa Clinical Response (HiSCR) were 0·73 and 0·51, respectively (P < 0·001 for both comparisons). SROCs with Dermatology Life Quality Index (DLQI), pain numerical rating scale and HS‐QoL were 0·42, 0·34 and –0·25, respectively (P < 0·001 for all comparisons). HS‐IGA was responsive at weeks 12 and 36. Predictive convergent validity was very good with HS‐PGA (area under the curve = 0·89) and with HiSCR (area under the curve = 0·82). Predictive divergent validity was low with DLQI and HS‐QoL. CONCLUSIONS: HS‐IGA has moderate‐to‐strong psychometric properties and is simple to calculate. John Wiley and Sons Inc. 2022-05-22 2022-08 /pmc/articles/PMC9542331/ /pubmed/35599448 http://dx.doi.org/10.1111/bjd.21236 Text en © 2022 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Garg, Amit Zema, Carla Kim, Katherine Gao, Weihua Chen, Naijun Jemec, Gregor B.E. Kirby, Joslyn Thorlacius, Linnea Villumsen, Bente Ingram, John R. Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials |
title | Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials
|
title_full | Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials
|
title_fullStr | Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials
|
title_full_unstemmed | Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials
|
title_short | Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials
|
title_sort | development and initial validation of the hs‐iga: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542331/ https://www.ncbi.nlm.nih.gov/pubmed/35599448 http://dx.doi.org/10.1111/bjd.21236 |
work_keys_str_mv | AT gargamit developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials AT zemacarla developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials AT kimkatherine developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials AT gaoweihua developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials AT chennaijun developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials AT jemecgregorbe developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials AT kirbyjoslyn developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials AT thorlaciuslinnea developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials AT villumsenbente developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials AT ingramjohnr developmentandinitialvalidationofthehsigaanovelhidradenitissuppurativaspecificinvestigatorglobalassessmentforuseininterventionaltrials |